Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth

Molecular Carcinogenesis

Volumn 54, Issue 3, 2015, Pages 167-177

  Cha, Tai Lung ^a,b   Chuang, Mei Jen ^a   Tang, Shou Hung ^a   Wu, Sheng Tang ^a   Sun, Kuang Hui ^c   Chen, Tzu Ting ^a,b   Sun, Guang Huan ^a   Chang, Sun Yran ^a,d   Yu, Cheng Ping ^a,b   Ho, Jar Yi ^a,b   Liu, Shu Yu ^a   Huang, Shih Ming ^b   Yu, Dah Shyong ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Bladder cancer; Emodin; Epigenetic modification; Phosphorylation of histone H3 at serine 10; Tri methylation of histone H3 at Lysine 27

Indexed keywords

COLLAGEN TYPE 8; COLLAGEN TYPE VIII ALPHA 1; EMODIN; FATTY ACID BINDING PROTEIN 4; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR BINDING PROTEIN 1; HISTONE H3; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG; WNT5B PROTEIN; HISTONE; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; EPIGENETICS; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CELL CYCLE CHECKPOINT; CHROMATIN IMMUNOPRECIPITATION; CYTOLOGY; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL CULTURE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; EMODIN; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84926108370     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22084     Document Type: Article

References (33)

1. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286-298.
2. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-1159.
3. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128:707-719.
4. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (New York, NY) 2002; 298:1039-1043.
5. Wei Y, Mizzen CA, Cook RG, Gorovsky MA, Allis CD. Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. Proc Natl Acad Sci USA 1998; 95:7480-7484.
6. Bode AM, Dong Z. Inducible covalent posttranslational modification of histone H3. Sci STKE 2005; 2005:re4.
7. Ausfeld R, Beer M, Muhlethaler JP, Bartlome F, Widmer R, Tscholl R. Adjuvant intravesical chemotherapy of superficial bladder cancer with monthly doxorubicin or intensive mitomycin. A comparison of two consecutive series. Eur Urol 1987; 13:10-14.
8. Rintala E, Jauhiainen K, Alfthan O, et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer. Eur Urol 1991; 20:19-25.
9. Seraphim LA, Perrapato SD, Slocum HK, Rustum YM, Huben RP. In vitro study of the interaction of doxorubicin, thiotepa, and mitomycin-C, agents used for intravesical chemotherapy of superficial bladder cancer. J Urol 1991; 145:613-617.
10. Battistutta R, Sarno S, De Moliner E, Papinutto E, Zanotti G, Pinna LA. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem 2000; 275:29618-29622.
11. Zhang L, Lau YK, Xi L, et al. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 1998; 16:2855-2863.
12. Olsen BB, Bjorling-Poulsen M, Guerra B. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: A study on its mechanism of action. Int J Biochem Cell Biol 2007; 39:227-237.
13. Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. Molecular mechanism of emodin action: Transition from laxative ingredient to an antitumor agent. Med Res Rev 2007; 27:591-608.
14. Huang XZ, Wang J, Huang C, et al. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: The mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 2008; 7:468-475.
15. Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (New York, NY) 2005; 310:306-310.
16. Cha TL, Chuang MJ, Wu ST, et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 2009; 15:840-850.
17. Ishizuka T, Lazar MA. The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol Cell Biol 2003; 23:5122-5131.
18. Dong Z, Bode AM. The role of histone H3 phosphorylation (Ser10 and Ser28) in cell growth and cell transformation. Mol Carcinog 2006; 45:416-421.
19. Chadee DN, Hendzel MJ, Tylipski CP, et al. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem 1999; 274:24914-24920.
20. Adams RR, Maiato H, Earnshaw WC, Carmena M. Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol 2001; 153:865-880.
21. Lin JG, Chen GW, Li TM, Chouh ST, Tan TW, Chung JG. Aloe-emodin induces apoptosis in T24 human bladder cancer cells through the p53 dependent apoptotic pathway. J Urol 2006; 175:343-347.
22. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003; 423:659-663.
23. Murnion ME, Adams RR, Callister DM, Allis CD, Earnshaw WC, Swedlow JR. Chromatin-associated protein phosphatase 1 regulates aurora-B and histone H3 phosphorylation. J Biol Chem 2001; 276:26656-26665.
24. Nowak SJ, Pai CY, Corces VG. Protein phosphatase 2A activity affects histone H3 phosphorylation and transcription in Drosophila melanogaster. Mol Cell Biol 2003; 23:6129-6138.
25. Olsen BB, Bjørling-Poulsen M, Guerra B. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: A study on its mechanism of action. Int J Biochem Cell Biol 2007; 39:227-237.
26. Celis JE, Østergaard M, Basse B, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996; 56:4782-4790.
27. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005; 11:4415-4429.
28. Nieman KM, Kenny HA, Penicka CV, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17:1498-1503.
29. Boiteux G, Lascombe I, Roche E, et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 2009; 124:1820-1828.
30. Elmasri H, Karaaslan C, Teper Y, et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009; 23:3865-3873.
31. Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002; 21:5733-5742.
32. Chen C, Benjamin MS, Sun X, et al. KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer 2006; 118:1346-1355.
33. Begum S, Zhang Y, Shintani T, Toratani S, Sato JD, Okamoto T. Immunohistochemical expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) as an angiogenic factor in head and neck tumorigenesis. Oncol Rep 2007; 17:591-596.